GENEVA, Switzerland October 19, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced two upcoming poster presentations on linzagolix, an oral GnRH antagonist, at the American Society for Reproductive Medicine (ASRM) 2021 Scientific Congress & Expo, being held October 17-20, 2021.
Details of the presentations are as follows:
Title: Efficacy and Safety of Linzagolix for the Treatment of Severe Adenomyosis: Final Results from a Pilot Study
Abstract: 11379
Poster Number: P-527
Presenter: Jacques Donnez
Session Date & Time: Poster presentation will be available through the ASRM conference portal, on Wednesday, October 20, 2021, from 6:30-7:45 a.m. ET
Title: Administration of Hormonal Add-Back Therapy (ABT) Counteracts the Uterine Volume Reducing Effects of Oral GnRH Antagonist Therapy
Abstract: 11462
Poster Number: P-503
Presenter: Jacques Donnez
Session Date & Time: Poster presentation will be available through the ASRM conference portal, on Wednesday, October 20, 2021, from 6:30-7:45 a.m. ET
The link to the session will be available under “Events Calendar” in the Investors section of ObsEva’s website at www.ObsEva.com
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com
